MediaPharma intends to advance its proprietary products portfolio to initial clinical safety and efficacy endpoints, then form strategic partnerships with companies that have the necessary commercialization infrastructures to best capture value.

Highlights

MediaPharma S.r.l.
A Company focused on the discovery and development of innovative drugs for the treatment of cancer and other diseases with unmet medical need.

Ultime News

Scientific Advisory Board

Members of MediaPharma’s Scientific Advisory Board include:

Franco Cavalli

Franco Cavalli is Scientific Director of the Oncology Institute of Southern Switzerland (IOSI) which has its main location in Bellinzona, Switzerland, but connects all the public hospitals of the Italian speaking part of Switzerland. He created this Institute, which encompasses medical oncology, radio-oncology, nuclear medicine, palliative care, hematology and an important research division. He is Professor (Titularprofessor) of medical oncology at the Medical Faculty in Bern (Switzerland). He has an international reputation for the treatment of and research into malignant lymphoma and new drugs. Every second year he organizes in Lugano the International Conference on Malignant Lymphoma, which is the most important congress on this topic worldwide.

Prof. Cavalli has been very active also in the field of the clinical evaluation of new drugs. In this field, he was chairman of the Early Clinical Trials Group of EORTC and created the SENDO (Southern Europe New Drug Organization), a conglomerate which included IOSI and the main cancer institutes in Milan.

The quality of his work has been recognized by the award of 21 national and international prices, including the Petzcoller award for special dedication to oncology and the Montaigne price. He has published more than 500 articles in peer-reviewed journals and has contributed to many books on cancer, including the Textbook of Medical Oncology, which he edited together with S. Kaye (London), H.H. Hansen (Copenhagen) and D. Armitage (Omaha, Nebraska). He was Founding Editor and Editor-in-Chief of Annals of Oncology, Europe’s premier medical oncology journal, from 1990 to 2000, and he is on the Editorial Board of several other journals. In 1996, he founded the International Extranodal Lymphoma Study Group (IELSG, www.ielsg.org), which encompasses now more than 200 institutions in 4 continents. IELSG is the leading cooperative group in the field of the biological and clinical studies in the field of extranodal lymphomas.

Prof. Cavalli has been President of the Swiss Cancer League and is Chairman of the scientific committee of the European School of Oncology (ESO). He was President of the International Union Against Cancer (UICC) between 2006 and 2008.

He was member of the Swiss Parliament between 1995 and 2007.

Fabio Malavasi

Professor of Medical Genetics at the University of Turin Medical School, Turin, Italy

Dr. Malavasi obtained an M.D. Degree at the Medical School, University of Ferrara, Italy.

During 1978-1982 he was Visiting Scientist at the Dept. of Medical Genetics, Mount Sinai School of Medicine, New York, N.Y., at Basel Institute for Immunology, Basel, Switzerland, and at the Sloan-Kettering Cancer Center, New York, N.Y.
In 1982 Prof. Malavasi was nominated Associate Professor of Cell Biology, University of Turin Medical School, Italy.
In 1985 he was Visiting Scientist, Lab of Cellular and Molecular Biology, Beth Israel Hospital, New York, N.Y.
In 1994 he was nominated Professor of Cell Biology at the University of Ancona Medical School, Ancona, Italy.

Giampaolo Tortora

Giampaolo Tortora is Professor of Medical Oncology and is Director of the Medical Oncology at the Medical School and University Hospital in Verona, Italy.

Prof. Tortora obtained a degree in Medicine, a Specialty in Oncology and a Ph.D. in Molecular Biology & Pathology. He also trained for five years at the National Cancer Institute in Bethesda, Maryland. His expertise lies in the identification and development of From Bench to Bedside drug products targeting growth factors receptors and signal transducers.

He has received several awards for his research.

Silvia Trasciatti

Silvia Trasciatti has a degree in Biological Sciences from the Università di Pisa, a 3-year specialization degree in Biotechnology from the Università di Milano and a Master in Nutritional Science from the Università di Firenze in Italy.

She spent several years working at the CNR (National Council of Research). She joined the Italian pharmaceutical company, Istituto Gentili, actively participating in the development of Alendronate, a drug for osteoporosis, eventually licenced to Merck & Co. At Abiogen Pharma, a spin-off company formed after the acquisition of Istituto Gentili by Merck & Co, Dr.

Trasciatti was actively involved in the development of neridronate, an orphan drug for osteogenesis imperfect, and started a fruitful collaboration with universities and research institutes in the field of oncology, coordinating the development of monoclonal antibodies and somatic cell therapies, from discovery to Phase II clinical trials.

As Director of the Research & Development Division at Abiogen Pharma, Dr. Trasciatti was also involved in licensing, business development and strategic planning. In 2011 Dr. Trasciatti was appointed Chief Scientific Officer (CSO) of the Italian biotech company Galileo Research, which is strongly focused on the development of an allogeneic cell therapy in oncology.

Dr. Trasciatti has a broad technical experience in the fields of pharmacology, toxicology and molecular biology, as well as, knowledge of GLP, GCP and international regulations for drug approval (ICH, FDA, EMEA, OECD) and patenting. Her scientific expertise range from bone and cartilage diseases, immunology, monoclonal antibodies, cancer immunotherapy.

Other professional achievements are represented by 14 patents, more than 15 projects advanced to clinical Phases and obtainment of 5 substantial research grants from the Italian government.

Daniel D. Von Hoff

Daniel D. Von Hoff, M.D., F.A.C.P. is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare’s Clinical Research Institute. He holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ.

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer.

Dr. Von Hoff has published more than 620 papers, 137 book chapters and over 1050 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

Company

R&D

Careers

Business

MediaPharma s.r.l. P.IVA.: IT 02282760699 | Rea di Chieti: 166532
The information provided on www.mediapharma.it is designed to complement, not replace, the relationship between a patient and his/her own physician.